Aller au contenu

Publications scientifiques

  • article Mansouri Z, Salimi Y, Akhavanallaf A, Shiri I, Teixeira EPA, Hou X, Beauregard JM, Rahmim A, Zaidi H

    Deep transformer-based personalized dosimetry from SPECT/CT images: a hybrid approach for [177Lu]Lu-DOTATATE radiopharmaceutical therapy

    Eur J Nucl Med Mol Imaging 51 (6), 2024.

    DOI PUBMED
  • article Hansen AR, Probst S, Beauregard JM, Viglianti BL, Michalski JM, Tagawa ST, Sartor O, Tutrone RF, Oz OK, Courtney KD, Delpassand ES, Nordquist LT, Osman MM, Chi KN, Sparks R, George N, Hawley SM, Wu W, Jensen JD, Fleshner NE

    Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohor…

    Front Oncol 14 2024.

    DOI PUBMED
  • article Schürrle SB, Eberlein U, Ansquer C, Beauregard JM, Durand-Gasselin L, Grønbæk H, Haug A, Hicks RJ, Lenzo NP, Navalkissoor S, Nicolas GP, Pais B, Volteau M, Wild D, McEwan A, Lassmann M

    Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours

    Eur J Nucl Med Mol Imaging 51 (8), 2024.

    DOI PUBMED
  • article Wild D, Grønbæk H, Navalkissoor S, Haug A, Nicolas GP, Pais B, Ansquer C, Beauregard JM, McEwan A, Lassmann M, Pennestri D, Volteau M, Lenzo NP, Hicks RJ

    A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours

    Eur J Nucl Med Mol Imaging 51 (1), 2023.

    DOI PUBMED
  • article Zahed H, Beauregard JM, Abikhzer G, Rush C, Probst S

    Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CT

    Clin Nucl Med 48 (1), 2023.

    DOI PUBMED
  • article Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J

    Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate …

    Lancet Oncol 24 (6), 2023.

    DOI PUBMED
  • article Beauregard JM, Rahmim A

    Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF)

    Eur J Nucl Med Mol Imaging 49 (2), 2022.

    DOI PUBMED
  • article Beauregard JM

    Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer

    Cancer Imaging 22 (1), 2022.

    DOI PUBMED
  • article Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ and

    Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

    N Engl J Med 385 (12), 2021.

    DOI PUBMED
  • article Hou X, Brosch J, Uribe C, Desy A, Böning G, Beauregard JM, Celler A, Rahmim A

    Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies

    J Nucl Med 62 (7), 2021.

    DOI PUBMED
  • article Hallqvist A, Svensson J, Hagmarker L, Marin I, Rydén T, Beauregard JM, Bernhardt P

    Optimizing the Schedule of PARP Inhibitors in Combination with Lu-DOTATATE: A Dosimetry Rationale

    Biomedicines 9 (11), 2021.

    DOI PUBMED
  • article Brosch-Lenz J, Yousefirizi F, Zukotynski K, Beauregard JM, Gaudet V, Saboury B, Rahmim A, Uribe C

    Role of Artificial Intelligence in Theranostics:: Toward Routine Personalized Radiopharmaceutical Therapies

    PET Clin 16 (4), 2021.

    DOI PUBMED